MRN ERN Banner
microRNA as Biomarkers and Diagnostic 2016 - microRNA生物標記診斷技術年會 2016年 -
2016年4月4日 - 2016年4月5日
美國,馬薩諸塞州,劍橋,Hyatt Regency Cambridge
microRNA as Biomarkers and Diagnostics

近年來研究顯示,小片段的非編碼microRNA可作為細胞過程的主要調控因子,表現模式也顯示其作為診斷、預後及治療反應生物標記的潛力。由Cambridge Healthtech Institute (CHI)所主辦的第12屆microRNA as Biomarkers and Diagnostics內容將包含microRNA在疾病的早期發現、癌症進程及治療反應的監控、了解免疫等方面的應用。此外也將討論對個人化醫療所造成的影響、microRNA生物標記的臨床應用等問題進行討論。

第1天 | 第2天


推薦參加晚餐短期課程 *

4月3日 (日) 、17:00 - 20:00
(短期課程1) 資料正規化的挑戰與對策

* 需額外報名


4月4日 (一)

7:00 年會報到手續、咖啡

8:00 年會董事的歡迎致詞


MICRORNA作為非侵襲性的診斷及預測生物標記

8:10 主席的開幕致詞

Ajay Goel, Ph.D., Professor and Director, Center for Gastrointestinal Research, and Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute, Baylor University Medical Center

8:15 大腸直腸癌的非編碼RNA生物標記

Ajay Goel, Ph.D., Professor and Director, Center for Gastrointestinal Research, and Director, Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research Institute, Baylor University Medical Center

Non-coding RNAs (ncRNAs) are emerging as important regulators of gene expression in cancer. Overexpression of specific non-coding RNAs (including microRNAs, snoRNAs, piRNAs and circular RNAs) has been linked to the stepwise disease progression in colorectal cancer (CRC). Given their cancer-specific pattern of expression, remarkable stability and presence in blood and other body fluids, ncRNAs are considered to be highly promising cancer biomarkers. Accumulating evidence firmly supports the existence of unique 'ncRNA signatures' that can not only facilitate earlier detection of the tumor, but can also assist in predicting disease recurrence and therapeutic outcome to current treatment regimens.

8:45 腎臟疾病的非侵襲性microRNA生物標記

Vishal S. Vaidya, Ph.D., Associate Professor, Medicine & Environmental Health, Harvard Medical School, Harvard T.H. Chan School of Public Health, Brigham and Women's Hospital

MiRNAs play a critical regulatory role in health and disease. Abundant expression, lower complexity, stability in various detection matrices and amplifiable signals are qualities that make extracellular miRNAs attractive as biomarkers reflecting a variety of pathophysiological conditions. We highlight the transformative potential of miRNAs as mechanistic biomarkers in translational medicine.

9:15 心血管疾病及機能障礙的環狀microRNA

Yuri D'Alessandra, Ph.D., Senior Researcher, Immunology and Functional Genomics Unit, Centro Cardiologico Monzino

Circulating microRNAs are emerging as biomarkers of several heart-related diseases. We have conducted studies encompassing many different cardiac maladies and identified specific circulating miRNAs as potential diagnostic markers.

9:45 贊助商演講(募集中)

10:15 展示會大廳休息、觀看海報


識別組織及生物流體中的MICRORNA生物標記

10:45 性別專一、族群專一、種族專一的調節性非編碼RNA

Isidore Rigoutsos, Ph.D., Professor and Director, Computational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University

By analyzing human transcriptomes from different people and different tissues, we found two types of short regulatory RNAs that are produced constitutively, and demonstrated that their composition and abundances depend on a person's gender, population and race as well as on tissue, tissue state, and disease subtype. The first type of short RNAs comprises numerous isoforms of mature microRNAs (miRNAs) that arise from virtually every known miRNA precursor. The second type of short RNAs comprises numerous fragments of mature transfer RNAs (tRNAs). We also discovered a novel category of tRNA fragments, the i-tRFs, which are wholly internal to the span of the mature tRNA and contribute much of the observed difference across individuals and tissues. The findings have direct implications for Precision Medicine and our understanding of the mechanisms underlying the onset and progression of disease.

11:15 識別多形性膠質母細胞瘤中預測存活率及治療反應的mircroRNA特徵

Sean Lawler, Ph.D., Assistant Professor, Neurosurgery, Brigham & Women's Hospital, Harvard Medical School

11:45 腎臟病患的microRNA特徵:組織及尿液資料庫中的統合分析

Christos Argyropoulos, M.D., Ph.D., MS, Assistant Professor, Nephrology, Department of Internal Medicine, University of New Mexico School of Medicine

MicroRNA (miRNA) are negative regulators of gene translation and an emerging biomarker in a wide variety of diseases. Little is known about the ability of miRNA to correctly classify patients with clinically significant renal pathology. We undertook a meta-analysis of miRNA profiles from clinical samples (biopsy or biofluid) in Gene Expression Omnibus. MiRNA profiles from 31 urine samples and 117 biopsy samples were available for analyses. A short signature of 19 miRNAs achieved a superior classification performance for renal pathology (cross-validated AUC 0.96).

12:15 午餐會演講或各自用餐


藥物開發的MICRORNA

1:25 主席致詞

Bing-Hua Jiang, Ph.D., Professor, Pathology, Anatomy and Cell Biology, Thomas Jefferson University

1:30 尋找腎小球傷害的泌尿系統microRNA生物標記

Rounak Nassirpour, Ph.D., Principal Scientist, Biomarkers Laboratory, Drug Safety R&D, Pfizer

Recent studies have reported significant levels of microRNAs in a variety of body fluids, raising the possibility that microRNAs could serve as useful biomarkers. Here we describe urinary microRNA expression alterations in preclinical models of kidney injury. The microRNAs identified may be promising translatable preclinical urinary biomarkers for drug-induced glomerular injury.

2:00 非侵襲性microRNA作為肝功能損傷生物標記以評估藥物安全

Xi Yang, Ph.D., Research Biologist, Systems Biology, National Center for Toxicological Research, FDA

Drug-induced liver injury is an important regulatory concern and a common reason for drug withdrawal. Acetaminophen (APAP) overdose is a major cause of acute liver failure in the Western world. Sensitive and specific biomarkers are required as diagnosis tools in the clinic and in screening assays during drug development stages. In our recent study, urinary miRNAs' potential as diagnostic biomarkers has been explored.

2:30 使用microRNA了解肺癌亞型的分化訊號傳遞與預測治療反應

Molly A. Taylor, Ph.D., Senior Scientist, AstraZeneca

We have classified three novel subtypes of lung squamous cell carcinoma that each have unique microRNA expression and therapeutic response profiles. Combined analysis of activated pathways and microRNA promoters has identified transcription factors driven by activated pathways that drive differences in microRNA expression. Overall, these microRNAs and transcription factors may function as biomarkers of pathway activation and aid in distinguishing patient subtypes to predict response to therapy.

3:00 展示會大廳休息、觀看海報

3:30 作為肝臟疾病反射的無細胞環狀microRNA

Steven Lockton, Ph.D., Senior Scientist, microMarkers, Regulus Therapeutics

MicroRNAs are stable in circulation and can be dysregulated with disease. Because microRNA expression is often organ-specific, cell-free circulating microRNA expression often reflects the diseased organ's pathophysiology. To map microRNAs to organs we profiled microRNA expression in mouse tissues. In a transgenic mouse model of hepatocellular carcinoma this serum reflection of liver distress was clearly demonstrated upon inducing HRAS. Similarly, in HCV-infected patients, aberrant serum microRNA expression was restored to a healthy-like state after treatment.

4:00 癌症microRNA與療法抗性

Bing-Hua Jiang, Ph.D., Professor, Pathology, Anatomy and Cell Biology, Thomas Jefferson University

We initially demonstrated that PI3K and AKT play an important role in tumor angiogenesis. We found recently that reactive oxygen species (ROS) levels are increased in ovarian, prostate and breast cancer cells; and are involved in activating PI3K/AKT and HER2/HER3 signaling and suppressing several key microRNAs for regulating cancer development, drug resistance, tumor growth and angiogenesis. We found that microRNA dysregulations regulate tumor growth, angiogenesis and drug resistance in several kinds of human cancers. To understand the potential link of ROS and microRNA dysregulations, we showed that ROS can suppress a number of microRNA expression through DNA methylation for inducing some pro-oncogene expression such as HER2/HER3. In addition, we find that miRNA depression is regulated by DNA methylation and transcriptional activation. MiRNA dysregulation is involved in cancer development, autophagy and therapeutic resistance.

4:30 贊助商演講(募集中)

5:00 展示會大廳的招待酒會、觀看海報

6:00 短期課程報到手續


推薦參加晚餐短期課程 *

4月4日 (一) 18:15 - 21:15
(短期課程2) 以microRNA為基礎的療法

* 需另行報名參加


第1天 | 第2天

4月5日 (二)

7:30 早餐時間的小組討論

Roundtable discussion are interactive, topic-specific discussions hosted by expert moderators and open to all attendees. These session provide a forum for discussing key issues.

  • Topic 1: Targeting of microRNAs for Therapeutics

    Moderator: Amy K. Patick, Ph.D., Principal, Patick Pharmaceutical and Scientific Consulting

  • Topic 2: Next-Generation Sequencing

    Moderator: Andreas Keller, Ph.D., Chair and Professor, Clinical Bioinformatics, University Hospital, Saarland University

  • Topic 3: miRNA as Cancer Biomarkers and Related Issues

    Moderator: Jingfang Ju, Ph.D., Associate Professor and Co-Director, Translational Research, Pathology, Stony Brook University

  • Topic 4: miRNAs and Exosomes

    Moderator: John Chevillet, Ph.D., Principal Scientist, N-of-One



NGS的挑戰

8:25 主席致詞

Andreas Keller, Ph.D., Chair and Professor, Clinical Bioinformatics, University Hospital, Saarland University

8:30 使用次世代定序(NGS)發現人類病理學的新血液感染microRNA

Andreas Keller, Ph.D., Chair and Professor, Clinical Bioinformatics, University Hospital, Saarland University

Although over 2,500 mature human miRNAs are known there is still a race for novel markers. Screening of blood cell fractions using NGS is a reasonable approach for discovering such minimally-invasive disease markers. With NGS as a high-throughput technique, however, a significant number of false positive biomarker candidates is reported. We present a complete pipeline: efficient discovery of novel miRNAs, filtering of false positives, and validation. The performance of the novel pipeline is demonstrated using neurological diseases as well as lung cancer.

9:00 使用支氣管上皮細胞的microRNA表現的肺癌偵測

Ana Brandusa Pavel, Ph.D., Researcher, Computational Biomedicine, Boston University School of Medicine

Using bronchial brushings from current and former smokers undergoing bronchoscopy for suspect lung cancer, we profiled microRNA expression via small RNAseq on the Illumina HiSeq 2000 platform. We found microRNA expression profiles significantly associated with lung cancer and that these microRNAs target mRNA whose expression was previously reported to be associated with lung cancer. Importantly, we show that integrating microRNA expression together with a gene-expression lung cancer biomarker increases performance.

9:30 贊助商演講(募集中)

9:45 展示會大廳休息、觀看海報


癌症路徑中MICRORNA所扮演的角色

10:25 主席致詞

Richard I. Gregory, Ph.D., Associate Professor, Department of Biological Chemistry and Molecular Pharmacology, Department of Pediatrics, Harvard Medical School, Harvard Stem Cell Institute, The Stem Cell Program at Boston Children's Hospital

10:30 microRNA在轉移性黑色素瘤中所扮演的預測性及功能性角色

Eva Hernando, Ph.D., Associate Professor and Vice Chair for Science, Department of Pathology; Co-Leader, Melanoma Program, NYU Langone Medical Center

Our laboratory has identified a miRNA signature in primary melanomas predictive of recurrence and metastasis. We have also demonstrated that some components of that signature which are lost in aggressive primary tumors act as metastasis suppressors. Our data supports that a miRNA-based prognostic assay could identify patients at higher risk of developing metastatic disease who could be subjected to increased surveillance or adjuvant therapies. Moreover our results support that miRNA changes can capture the molecular heterogeneity that dictates metastatic behavior since early tumor stages.

11:00 microRNA在癌症中的生合成路徑

Richard I. Gregory, Ph.D., Associate Professor, Department of Biological Chemistry and Molecular Pharmacology, Department of Pediatrics, Harvard Medical School, Harvard Stem Cell Institute, The Stem Cell Program at Boston Children's Hospital

Amplification and overexpression of individual 'oncomiRs' or genetic loss of tumor suppressor miRNAs promotes tumorigenesis. Furthermore, global miRNA depletion caused by genetic and epigenetic alterations in components of the miRNA biogenesis machinery is oncogenic. This, together with the recent identification of novel miRNA regulatory factors and pathways, highlights the importance of miRNA dysregulation in cancer.

11:30 透過Smad2及自噬作用,使用miR-140根除大腸癌幹細胞

Jingfang Ju, Ph.D., Associate Professor and Co-Director, Translational Research, Pathology, Stony Brook University

Colorectal cancer (CRC) is the third highest mortality cancer in the US and frequently metastasizes to liver and lung. Smad2 is a key element downstream of the TGF-β signaling pathway to regulate cancer metastasis by promoting epithelial to mesenchymal transition and maintaining the cancer stem cell (CSC) phenotype. In this study, we show that hsa-miR-140-5p directly targets Smad2 and overexpression of hsa-miR-140-5p in CRC cell lines decreases Smad2 expression levels, leading to decreased cell invasion and proliferation, and increasing cell cycle arrest. The functional and clinical significance of hsa-miR-140-5p suggests that it is a key regulator in CRC progression and metastasis, and may have potential as a novel therapeutic molecule to treat CRC.

12:00 年會閉幕



第1天 | 第2天

* 活動內容有可能不事先告知作更動及調整。


Choose your language
Chinese
Japanese
Korean
English

View Media Partners


Catalog

 
產業會議彙總曆
製藥相關國際會議
免費電子郵件通知服務
免費電子郵件通知服務

CHI | Cambridge HealthTech Institute
中文官方網站營運:Cambridge HealthTech Institute代理商 日商環球訊息有限公司